Drug Type Small molecule drug |
Synonyms INV-101, MRI-1867, S-MRI-1867 |
Target |
Mechanism CB1 inverse agonists(Cannabinoid CB1 receptor inverse agonists), NOS2 inhibitors(Nitric oxide synthase, inducible inhibitors) |
Therapeutic Areas |
Originator Organization Inversago Pharma, Inc.Startup |
Active Organization Inversago Pharma, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21ClF3N5O2S |
InChIKeyNLXIJZHFEOSWPU-JOCHJYFZSA-N |
CAS Registry1998760-00-1 |
Start Date08 Sep 2020 |
Sponsor / Collaborator Inversago Pharma, Inc.Startup |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 1 | CA | Inversago Pharma, Inc.Startup | 29 Sep 2020 |
Prader-Willi Syndrome | Phase 1 | CA | Inversago Pharma, Inc.Startup | 29 Sep 2020 |
Idiopathic Pulmonary Fibrosis | Preclinical | CA | Inversago Pharma, Inc.Startup | 11 Aug 2023 |
Progressive pulmonary fibrosis | Preclinical | CA | Inversago Pharma, Inc.Startup | 14 Sep 2020 |
Hermanski-Pudlak Syndrome | Preclinical | CA | Inversago Pharma, Inc.Startup | 07 Sep 2020 |
Interstitial lung disease due to systemic disease | Preclinical | CA | Inversago Pharma, Inc.Startup | 07 Sep 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |